Journal article
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial
Abstract
BACKGROUND: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood-brain barrier.
METHODS: European Organisation for Research and Treatment of …
Authors
Roth P; Gorlia T; Reijneveld JC; de Vos F; Idbaih A; Frenel J-S; Le Rhun E; Sepulveda JM; Perry J; Masucci GL
Journal
Neuro-Oncology, Vol. 26, No. 9, pp. 1670–1682
Publisher
Oxford University Press (OUP)
Publication Date
September 5, 2024
DOI
10.1093/neuonc/noae053
ISSN
1522-8517